CN110179788A - Application of the moracin in preparation treatment fatty liver medicament - Google Patents
Application of the moracin in preparation treatment fatty liver medicament Download PDFInfo
- Publication number
- CN110179788A CN110179788A CN201910592850.8A CN201910592850A CN110179788A CN 110179788 A CN110179788 A CN 110179788A CN 201910592850 A CN201910592850 A CN 201910592850A CN 110179788 A CN110179788 A CN 110179788A
- Authority
- CN
- China
- Prior art keywords
- moracin
- fatty liver
- group
- application
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
The invention discloses a kind of application of moracin in preparation treatment fatty liver medicament.The present invention is had found for the first time by scientific experiment, moracin can reduce the intracellular accumulation of lipid of steatosis HepG2 of oleic acid induction, inhibit cytolipin intake, the protein expression of PPARa, LDLR, CYP7A1 can be raised, have the function of apparent effect for reducing fat and improve nonalcoholic fatty liver, is expected to develop into the pharmaceutical preparation of prevention and treatment nonalcoholic fatty liver using moracin as active constituent.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, in particular to a kind of moracin answering in preparation treatment fatty liver medicament
With.
Background technique
Nonalcoholic fatty liver (nonalcoholic fatty liverdisease, NAFLD) is a kind of common metabolism
Property disease, using no excessive drinking history, hepatic cell fattydegeneration and lipidosis as major pathologic features.From fatty liver to liver cancer only
Need four-stage: fatty liver, nonalcoholic steatohepatitis and liver fibrosis, cirrhosis and hepatocellular carcinoma.Fatty liver is not only
A kind of independent disease can also cause the generation of a variety of comorbidities such as obesity, diabetes along with patient blood glucose, the influence of blood lipid.Greatly
Part obese patient is with hepatic steatosis.With the improvement of people's living standards, NAFLD is with its high illness rate, low age
The factors such as change trend and Chronic Progressive process, have become the big chronic liver disease in the whole world first including China.Due to people
Very big variation also occurs for the aggravation of the aging process of mouth, the spectrum of disease of liver.More and more research confirmations, NAFLD's
Clinic burden is not limited only to liver, the even more independent risk factor of the outer complication (cardiovascular disease, malignant tumour etc.) of liver.At present
Treatment for NAFLD there is no specific medicament, therefore seeks to prevent and treat the effective monomer component of NAFLD from Chinese medicine and study its work
With the hot spot that mechanism is in ongoing research area.
NAFLD starts from the lipid accumulation of liver, and research lipid-metabolism mechanism becomes an important direction.In lipid-metabolism
In, peroxisome proliferation activated receptor a (peroxime proliferator-activated receptors a,
PPARa fatty acid oxidation) is played, is the nuclear receptor that a height is expressed in liver, it can be to participation fatty acid oxidation, absorption
Transcription is played with the gene of inflammation.7a hydroxylase (CYP7A1) is the key enzyme of primary bile acid synthesis, to maintenance body
Cholesterol homeostasis is most important.In addition, what most of plasma cholesterol in human body was mediated by ldl receptor (LDLR)
The antiport that intake and HDL- are mediated returns in liver to be metabolized again.LDLR expression or active increase, can be enhanced absorption blood
LDL-C in slurry, so that the LDL-C reduced in blood plasma is horizontal.
Moracin (Morusin, No. CAS is 62596-29-6), also known as morusin, are from the moraceae plants root bark of white mulberry
The active monomer component isolated in (Moru salba L.), molecular formula C24H25O6, molecular weight 420.46, molecular structure
Formula is as follows:
Studies have shown that moracin has antitumor, improvement cognitive disorder, inhibition triglycerides (TG) synthesis,
By inducing cell apoptosis and inhibiting Agiogenesis inhibition hepatoma cell proliferation on internal levels in vitro；By the table for inhibiting Bax
Up to inducing cell apoptosis, to inhibit the survival of human breast cancer cell；The Rats With Memory damage of ALCL3 induction can be significantly improved
Wound, can improve cognitive disorder, have potential protective effect.In addition, fat is thin before moracin can also significantly inhibit 3T3-L1
The inhibiting rate of the differentiation of born of the same parents, TG reaches 56%, reaches 70% to the inhibiting rate of GPDH (glycerol triphosphate dehydrogenase).But arrive mesh
Before until, whether moracin has the function of effect for reducing fat and its in nonalcoholic fatty liver there is not yet relevant report.
Summary of the invention
In order to solve problems in the prior art, the embodiment of the invention provides a kind of moracins treats fatty liver medicine in preparation
Application in object.The technical solution is as follows:
In a first aspect, application of the moracin in preparation up-regulation PPARa protein expression drug.
Second aspect, application of the moracin in preparation up-regulation LDLR protein expression drug.
The third aspect, application of the moracin in preparation up-regulation CYP7A1 protein expression drug.
4th on the one hand, application of the moracin in preparation treatment fatty liver medicament.
Further, the fatty liver is specially nonalcoholic fatty liver.
Further, the treatment fatty liver medicament includes tablet, pill, capsule, injection, sustained release agent and controlled release
Agent.
Technical solution provided in an embodiment of the present invention has the benefit that the present invention is sent out for the first time by scientific experiment
Existing, moracin can reduce the intracellular accumulation of lipid of steatosis HepG2 of oleic acid induction, inhibit cytolipin intake, can on
The protein expression for adjusting PPARa, LDLR, CYP7A1 has the function of apparent effect for reducing fat and improvement nonalcoholic fatty liver, with
Moracin is expected to develop into the pharmaceutical preparation of prevention and treatment nonalcoholic fatty liver as active constituent.
Detailed description of the invention
The technical solution in example is applied in order to illustrate more clearly of the present invention, it below will be to required use in embodiment description
Attached drawing be briefly described.
Fig. 1 be in the embodiment of the present invention various concentration moracin to HepG2 cell-proliferation activity influence diagram；
Fig. 2 be in the embodiment of the present invention various concentration oleic acid to the influence diagram of HepG2 cell-proliferation activity；
Fig. 3 be in the embodiment of the present invention 300nM oleic acid to HepG2 cell induction for 24 hours after oil red O cell dyeing figure；
Fig. 4 is that the oil red O for the HepG2 cell that various concentration moracin induces 300nM oleic acid in the embodiment of the present invention is thin
Born of the same parents' colored graph；
Fig. 5 is the lipid content for the HepG2 cell that various concentration moracin induces 300nM oleic acid in the embodiment of the present invention
Measurement chart；
Fig. 6 is the Dil-LDL for the HepG2 cell that various concentration moracin induces 300nM oleic acid in the embodiment of the present invention
Absorb influence diagram；
Fig. 7 be the HepG2 cell PPARa that various concentration moracin induces 300nM oleic acid in the embodiment of the present invention,
The histogram of LDLR, CYP7A1 protein expression；
Various concentration moracin induces 300nM oleic acid in Fig. 8 embodiment of the present invention HepG2 cell PPARa, LDLR,
The influence diagram of CYP7A1 protein expression.
Specific embodiment
To make the object, technical solutions and advantages of the present invention clearer, below in conjunction with attached drawing to embodiment party of the present invention
Formula is described in further detail.
Embodiment
(1) influence of the moracin to HepG2 cell Proliferation
By HepG2 cell suspension inoculation in 96 orifice plates, 104100 μ l of culture medium is added in/hole, every hole, and cell is not added in first row
Only plus culture solution is as blank group, and second is classified as cell under normal physiological condition as a control group, other are respectively classified as place
Cell under normal physiological condition, as administration group, every group of 5 multiple holes.When cell density grows to 80-90% or so, inhale
Supernatant is abandoned, dosing group gives various concentration moracin (1,2.5,5,10,20,40 μM), and control group is given containing 0.08%DMSO
Culture medium, intervene for 24 hours, inhale and abandon culture medium, mix CCK8 reagent and culture medium according to 1:10, it is mixed that 100 μ l are added to every hole
Culture medium after even, continuation are incubated for 1-4h in incubator, measure OD value of each hole under 450nm wavelength using microplate reader, weight
It is multiple to be averaged three times, calculate cell survival rate.Cell survival rate=[(dosing group OD value-blank group OD value)/(control group OD
Value-blank group OD value)] * 100%.
As a result as shown in Figure 1, this experiment acts on HepG2 cell first with a series of more wide in range moracin concentration,
Its cell activity is measured, after 24 to determine the substantially concentration of moracin effect in subsequent experimental.At concentration >=20 μM, cell
Active conspicuousness reduces, therefore considers that 2.5,5,10 μM are used as subsequent experimental research.In Fig. 1, compared with the control group, * * * P <
0.001。
(2) foundation of oleic acid (OA) induction HepG2 cellular fat liver fibrosis models
A, CCK-8 method filters out the OA molar concentration of no cytotoxicity
After the HepG2 cell dissociation of logarithmic growth phase, after the RPM640 culture medium dilution containing 10%FBS, it is inoculated in
96 orifice plates, 104/ hole, every hole are added 100 μ l of culture medium, are divided into blank group, control group and model group, every group of 5 multiple holes.To thin
When born of the same parents' density grows to 80-90% or so, inhale abandon supernatant, model group give various concentration sodium oleate solution (0.1,0.3,0.5,
0.8mM), control group gives the culture medium containing 1%BSA, intervenes for 24 hours, inhales and abandon culture medium, according to 1:10 by CCK8 reagent and culture
Base mixes, and the culture medium after 100 μ l are mixed is added to every hole, and continuation is incubated for 1-4h in incubator, measures using microplate reader each
OD value of the hole under 450nm wavelength calculates cell survival rate.
As a result as shown in Fig. 2, with OA concentration raising, HepG2 cell-proliferation activity is on a declining curve.With 0mM concentration
Group compares, and after the effect for 24 hours of 300mM oleic acid, cell-proliferation activity, which is not affected by, to be substantially change, and the oleic acid of 500mM, 800mM are to thin
Born of the same parents' proliferation activity is in be decreased obviously.Therefore, in order to reduce influence of the oleic acid to hepatotoxicity, follow-up test considers 300mM oil
Acid effect induces HepG2 cell for 24 hours.In Fig. 2 compared with the control group, P < 0.01 * *.
B, the fat drips formational situation of nontoxic OA is observed using oil red O stain
After the HepG2 cell dissociation of logarithmic growth phase, after the RPM640 culture medium dilution containing 10%FBS, it is inoculated in 6
Orifice plate, 5 × 105/ hole, every hole 2ml cell suspension.It when cell density grows to 80-90% or so, inhales and abandons supernatant, model group is given
The sodium oleate solution of various concentration is given, control group gives the culture medium containing 1%BSA, intervenes for 24 hours, inhales and abandon culture medium, with 1ml's
PBS is washed 1 time, adds the fixed 30min of 4% paraformaldehyde room temperature of 1ml, then washed 1 time with PBS.Refuel red O working solution in every hole
1ml is incubated at room temperature 20min.Dyeing liquor is discarded, is washed 2 times with PBS, fat drips formational situation is observed under inverted microscope and is clapped
According to record.
As shown in figure 3, being carried out using oil red O to cell dyeing when being induced for 24 hours using 300mM oleic acid liver cell
It identifies, red fat drips particle obviously increases in visible cell under microscope, prompts this research modeling success.
(3) influence of the moracin of various concentration to the OA HepG2 cytolipin content induced
After the HepG2 cell dissociation of logarithmic growth phase, after the RPM640 culture medium dilution containing 10%FBS, it is inoculated in
96 orifice plates, 104/ hole, every hole are added 100 μ l of culture medium, are divided into control group, OA group and dosing group, every group of 5 multiple holes.To cell
It when density grows to 70% or so, inhales and abandons supernatant, in addition to control group, other each groups are added 0.3mM OA solution and add after induction for 24 hours
Medicine group gives the moracin (2.5,5,10 μM) of various concentration, intervenes for 24 hours, inhales and abandon culture medium, washed 1 time, added with the PBS of 1ml
4% paraformaldehyde room temperature of 1ml fixes 30min, then is washed 1 time with PBS.Refuel red O working solution 1ml in every hole, incubation at room temperature
20min.Dyeing liquor is discarded, is washed 2 times with PBS, 100 μ l, 60% isopropanol is added in every hole, and incubation at room temperature 10min is shaken
Extracting measures OD value in 520nm wavelength, calculates lipid content.
As shown in figure 4, oil red O stain the result shows that, compared with normal group, the intracellular red fat drips particle of OA group increases.
Compared with OA group, intracellular red fat drips number is substantially reduced in moracin processing group, and as the increase oil droplet number of dosage is more next
It is fewer.It by the measurement (Fig. 5) of lipid content, finds compared with normal group, OA group lipid content is significantly raised.With OA group phase
Than the lipid content of moracin various concentration processing group is substantially reduced, and as the increase of dosage reduction is more obvious, prompts Sang Xin
Element can reduce lipid content in cell.In Fig. 5, compared with the control group, ##P < 0.01；Compared with OA group, * P < 0.05, * * P <
0.01。
(4) influence that the moracin of various concentration absorbs HepG2 cell Dil-LDL
After the HepG2 cell dissociation of logarithmic growth phase, after the RPM640 culture medium dilution containing 10%FBS, it is inoculated in
96 orifice plates, 104/ hole, every hole are added 100 μ l of culture medium, are divided into control group, OA group and dosing group, every group of 5 multiple holes.To cell
It when density grows to 70% or so, inhales and abandons supernatant, in addition to control group, other each groups are added 0.3mM OA solution and add after induction for 24 hours
Medicine group gives the moracin (2.5,5,10 μM) of various concentration, intervenes for 24 hours, inhales and abandon culture medium, washs 1 time with the PBS of 1ml, often
The Dil-LDL of 10mg/L is added in hole, is protected from light and is incubated for 5h.The culture solution in hole is sopped up, the PBS shaking table that the BSA of 4g/L is added washes 2 ×
5min, PBS are softly washed 3 times.Add the fixed 30min of 4% paraformaldehyde room temperature of 1ml, then is washed 3 times with PBS.DAPI dyeing
20min is washed 3 times with PBS.Remaining night is exhausted, the anti-fluorescent quenching liquid of drop is added dropwise in every hole, and fluorescence microscopy is taken pictures under the microscope.
As shown in fig. 6, the intracellular red fluorescence of OA group HepG2 dramatically increases compared with normal group.Compared with OA group, mulberry
The pungent element intracellular red fluorescence of various concentration processing group HepG2 significantly reduces, and with the increase of dosage, reduction is more obvious.It mentions
Show that moracin can inhibit HepG2 cell LDL intake.
(5) influence of the moracin of various concentration to OA HepG2 cell PPARa, LDLR, CYP7A1 protein expression induced
After the HepG2 cell dissociation of logarithmic growth phase, after the RPM640 culture medium dilution containing 10%FBS, it is inoculated in 6
Orifice plate, 5 × 105/ hole, every hole 2ml cell suspension.It is divided into control group, OA group and dosing group, grows to 70% or so to cell density
When, it inhales and abandons supernatant, in addition to control group, 0.3mMOA solution is added in other each groups, and after induction for 24 hours, dosing group gives various concentration
Moracin (2.5,5,10 μM) intervenes for 24 hours, inhales and abandon culture medium, cleaned 2 times with the PBS of pre-cooling, the cell cracking of 120 μ l is added
Liquid (concentration of protease inhibitors PMSF be 1mM), cracks 30min on ice, every 10min in vibrating 30s on turbula shaker.
Cell scraper by under the cell scraper in six orifice plates, is collected into 1.5ml centrifuge tube in the same direction.Then low-temperature centrifugation
(12000g be centrifuged × 15 minutes), draws supernatant, and bicinchoninic acid (BCA) method measures protein concentration, -80 DEG C freeze it is spare.
10% lauryl sodium sulfate (SDS) polyacrylamide gel electrophoresis protein isolate sample, with 1 × TBS (triethanolamine buffered salt
Aqueous solution) rinsing is once.Block buffer is added, is placed in oscillation shaking table and is closed (room temperature, 80rpmmin-1, 1h).It abandons
Confining liquid is placed in 4 DEG C and was hybridized using 5%BSA confining liquid dilution primary antibody (antibody PPARa, LDLR, CYP7A1,1:1000)
Night.Morning next day recycles primary antibody hybridization solution, washes film 3 times with TBST and (is placed in oscillation shaking table, room temperature, 80rpmmin-1,
10min times-1).TBST is abandoned, secondary antibody (1:5000) is diluted to debita spissitudo with 5%BSA, and 5ml is added, and is placed in oscillation shaking table
Hybridized (room temperature, 80rpmmin-1, 1h).Two corresponding anti-solution is abandoned, film 3 times is washed with TBST and (is placed in shaking table, room temperature, 80r
min-1, 10min times-1).It is appropriate to be added dropwise on luminescence reagent ECL working solution to film according to the size of film, it places 1 minute.It utilizes
Gel imaging system acquires image, and Image pro Plus6.0 software carries out image analysis.
As shown in Figure 7 and Figure 8, compared with 0 μM of group, the protein expression level of PPARa, LDLR, CYP7A1 in OA group are aobvious
Writing reduces.Compared with OA group, the protein expression level of PPARa, LDLR, CYP7A1 in moracin various concentration processing group are obvious
It increases, lipid-metabolism is influenced by PPARa approach when prompting moracin possible.
The present invention has found that the steatosis HepG2 that moracin can reduce oleic acid induction is intracellular by scientific experiment for the first time
Accumulation of lipid, inhibit cytolipin intake, the protein expression of PPARa, LDLR, CYP7A1 can be raised, have apparent lipid-loweringing
Effect and the effect for improving nonalcoholic fatty liver are expected exploitation using moracin as active constituent into prevention and treatment non-alcoholic fatty
The pharmaceutical preparation of liver.
The serial number of the above embodiments of the invention is only for description, does not represent the advantages or disadvantages of the embodiments.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, it is all in spirit of the invention and
Within principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (6)
1. application of the moracin in preparation up-regulation PPARa protein expression drug.
2. application of the moracin in preparation up-regulation LDLR protein expression drug.
3. application of the moracin in preparation up-regulation CYP7A1 protein expression drug.
4. application of the moracin in preparation treatment fatty liver medicament.
5. application as claimed in claim 4, which is characterized in that the fatty liver is specially nonalcoholic fatty liver.
6. application as claimed in claim 4, which is characterized in that the treatment fatty liver medicament includes tablet, pill, capsule
Agent, injection, sustained release agent and controlled release agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910592850.8A CN110179788A (en) | 2019-07-03 | 2019-07-03 | Application of the moracin in preparation treatment fatty liver medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910592850.8A CN110179788A (en) | 2019-07-03 | 2019-07-03 | Application of the moracin in preparation treatment fatty liver medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110179788A true CN110179788A (en) | 2019-08-30 |
Family
ID=67724824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910592850.8A Pending CN110179788A (en) | 2019-07-03 | 2019-07-03 | Application of the moracin in preparation treatment fatty liver medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110179788A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181296A2 (en) * | 2012-05-29 | 2013-12-05 | Unigen, Inc. | Compositions and methods for managing weight |
| CN108785370A (en) * | 2017-05-05 | 2018-11-13 | 中国科学院上海药物研究所 | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis |
-
2019
- 2019-07-03 CN CN201910592850.8A patent/CN110179788A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181296A2 (en) * | 2012-05-29 | 2013-12-05 | Unigen, Inc. | Compositions and methods for managing weight |
| CN108785370A (en) * | 2017-05-05 | 2018-11-13 | 中国科学院上海药物研究所 | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis |
Non-Patent Citations (3)
| Title |
|---|
| MI RIM LEE ET AL.: "Morusin Functions as a Lipogenesis Inhibitor asWell as a Lipolysis Stimulator in Differentiated 3T3-L1 and Primary Adipocytes", 《MOLECULES.》 * |
| TSUI-HWA TSENG ET AL.: "Protective Effects of Morus Root Extract (MRE) Against Lipopolysaccharide-Activated RAW264.7 Cells and CCl4-Induced Mouse Hepatic Damage", 《 CELL PHYSIOL BIOCHEM. 》 * |
| 徐微微等: "《临床内科常见疾病学》", 30 June 2018, 上海交通大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Anti-rheumatic properties of gentiopicroside are associated with suppression of ROS-NF-κB-NLRP3 axis in fibroblast-like synoviocytes and NF-κB pathway in adjuvant-induced arthritis | |
| CN109843298A (en) | The combination treatment of utilization method Buddhist nun ester X receptor (FXR) regulator | |
| Jue et al. | COE inhibits vasculogenic mimicry in hepatocellular carcinoma via suppressing Notch1 signaling | |
| Wei et al. | Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway | |
| Zhang et al. | Neuroprotective role of epigallocatechin‑3‑gallate in acute glaucoma via the nuclear factor‑κB signalling pathway | |
| CN102370738B (en) | Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof | |
| Li et al. | Anti-inflammatory activity of mollugin on DSS-induced colitis in mice | |
| CN101559049A (en) | Hepatic fibrosis inhibitor | |
| CN105878233B (en) | Application of the artemisinin derivative in preparation treatment hepatic fibrosis medicines | |
| CN104906111A (en) | Pharmaceutical composition prepared from hydroxytyrosol for treating liver injury and preparation process of pharmaceutical composition | |
| CN110179788A (en) | Application of the moracin in preparation treatment fatty liver medicament | |
| CN107349190A (en) | The application of ar-turmerone | |
| RU2549441C2 (en) | Methods and pharmaceutical compositions for treating down syndrome | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| CN105534971B (en) | Dibenzo oxepin class compound screens or prepares in vitro the application in drug | |
| CN103037901B (en) | Suppress CD36 with obesity controlling and insulin sensitivity | |
| CN108653296A (en) | The application of elemi eleostearic acid and the drug for treating pancreatitis | |
| Higuchi et al. | Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy | |
| CN104161765A (en) | Application of platycodin D in preparing medicaments for inhibiting angiogenesis | |
| Ding et al. | Cassiae Semen improves non-alcoholic fatty liver disease through autophagy-related pathway | |
| CN109280069A (en) | 3 β -hydroxy-ergosta-5-ene steroid derivatives and their pharmaceutical use | |
| WO2016082807A2 (en) | New use of itraconazole | |
| CN106974916A (en) | Compound and its application of shellfish cholic acid and melbine difficult to understand | |
| KR20140040359A (en) | Pharmaceutical compositions for prevention or treatment of liver cancer comprising neferine | |
| CN105147701B (en) | The effective component of chinese medicine compound preparation and application thereof for treating non-alcohol fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |